Conclusion: Health care providers must consider the efficacy, GI and cardiovascular risks, concomitant medications, and costs when determining the appropriateness of COX-2-selective NSAID therapy.
Lp(a) HORIZON aims to show superiority for the antisense drug over placebo in reducing major cardiovascular events (MACE) in patients with established cardiovascular disease and elevated levels of ...
So, will Merck make its $10 billion target for cardiovascular drugs? No doubt, according to analyst Akash Tewari of Jefferies, who reckons that sotatercept will become a $7.5 billion drug at peak ...
ISLAMABAD, Dec 21 (APP): BRI Veterinary Drug and Vaccine Symposium 2024 kicked off in Beijing under the Advanced Workshop on Veterinary Drug and Vaccine Technology in BRI Countries, bringing together ...
ISLAMABAD, Dec 22 (APP):BRI Veterinary Drug and Vaccine Symposium 2024 kicked off in Beijing under the Advanced Workshop on Veterinary Drug and Vaccine Technology in BRI Countries, bringing together ...
The amendments were outlined in the Draft guidance on terms and conditions (T&Cs) for human and veterinary drugs. This draft guidance gave information on the: proposed regulatory authority for T&Cs as ...